» Articles » PMID: 26105525

Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice

Overview
Specialty Pharmacology
Date 2015 Jun 25
PMID 26105525
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Time is an important aspect of health economic evaluation, as the timing and duration of clinical events, healthcare interventions and their consequences all affect estimated costs and effects. These issues should be reflected in the design of health economic models. This article considers three important aspects of time in modelling: (1) which cohorts to simulate and how far into the future to extend the analysis; (2) the simulation of time, including the difference between discrete-time and continuous-time models, cycle lengths, and converting rates and probabilities; and (3) discounting future costs and effects to their present values. We provide a methodological overview of these issues and make recommendations to help inform both the conduct of cost-effectiveness analyses and the interpretation of their results. For choosing which cohorts to simulate and how many, we suggest analysts carefully assess potential reasons for variation in cost effectiveness between cohorts and the feasibility of subgroup-specific recommendations. For the simulation of time, we recommend using short cycles or continuous-time models to avoid biases and the need for half-cycle corrections, and provide advice on the correct conversion of transition probabilities in state transition models. Finally, for discounting, analysts should not only follow current guidance and report how discounting was conducted, especially in the case of differential discounting, but also seek to develop an understanding of its rationale. Our overall recommendations are that analysts explicitly state and justify their modelling choices regarding time and consider how alternative choices may impact on results.

Citing Articles

Methods for extrapolating costs and effects in economic evaluations of telehealth interventions: a scoping review protocol.

Raunbak S, Weinreich U, Johnsen S, Udsen F BMJ Open. 2025; 14(12):e087676.

PMID: 39806705 PMC: 11664371. DOI: 10.1136/bmjopen-2024-087676.


Trends and changes in the relationship between quality and price in tenders for healthcare services in the Israeli health system, 2013-2023.

Niv-Yagoda A, Goldshtein H BMC Health Serv Res. 2024; 24(1):1596.

PMID: 39695563 PMC: 11654431. DOI: 10.1186/s12913-024-11963-4.


A systematic review on the appropriate discounting rates for the economic evaluation of gene therapies: whether a specific approach is justified to tackle the challenges?.

Qiu T, Aballea S, Pochopien M, Toumi M, Dussart C, Yan D Int J Technol Assess Health Care. 2024; 40(1):e23.

PMID: 38725378 PMC: 11569993. DOI: 10.1017/S0266462324000096.


Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force.

Henry E, Al-Janabi H, Brouwer W, Cullinan J, Engel L, Griffin S Pharmacoeconomics. 2023; 42(3):343-362.

PMID: 38041698 PMC: 10861630. DOI: 10.1007/s40273-023-01321-3.


Economic Evaluation of Exercise or Cognitive and Social Enrichment Activities for Improved Cognition After Stroke.

Adjetey C, Davis J, Falck R, Best J, Dao E, Bennett K JAMA Netw Open. 2023; 6(11):e2345687.

PMID: 38032638 PMC: 10690466. DOI: 10.1001/jamanetworkopen.2023.45687.


References
1.
Mauskopf J . Prevalence-based economic evaluation. Value Health. 2006; 1(4):251-9. DOI: 10.1046/j.1524-4733.1998.140251.x. View

2.
Soares M, Canto E Castro L . Continuous time simulation and discretized models for cost-effectiveness analysis. Pharmacoeconomics. 2012; 30(12):1101-17. DOI: 10.2165/11599380-000000000-00000. View

3.
Paulden M, Claxton K . Budget allocation and the revealed social rate of time preference for health. Health Econ. 2011; 21(5):612-8. DOI: 10.1002/hec.1730. View

4.
Karnon J . Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ. 2003; 12(10):837-48. DOI: 10.1002/hec.770. View

5.
Chhatwal J, He T . Economic evaluations with agent-based modelling: an introduction. Pharmacoeconomics. 2015; 33(5):423-33. DOI: 10.1007/s40273-015-0254-2. View